Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v9-EN | Version v8-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2024-10-23 | 2024-10-11 |
| Drug Identification Number | 02492415 | 02492415 |
| Brand name | BAQSIMI | BAQSIMI |
| Common or Proper name | Glucagon Nasal Powder | Glucagon Nasal Powder |
| Company Name | AMPHASTAR PHARMACEUTICALS, INC. | AMPHASTAR PHARMACEUTICALS, INC. |
| Ingredients | GLUCAGON | GLUCAGON |
| Strength(s) | 3MG | 3MG |
| Dosage form(s) | POWDER | POWDER |
| Route of administration | NASAL NASAL | NASAL NASAL |
| Packaging sizes (GTIN) | (See additional packaging sizes) | (See additional packaging sizes) |
| Additional packaging sizes | 3 mg glucagon per device | 3 mg glucagon per device |
| ATC code | H04AA | H04AA |
| ATC description | GLYCOGENOLYTIC HORMONES | GLYCOGENOLYTIC HORMONES |
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | 2024-10-10 | 2024-10-10 |
| Actual start date | 2024-10-10 | 2024-10-10 |
| Estimated end date | 2024-10-28 | 2024-10-28 |
| Actual end date | 2024-10-22 | |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | The demands have been higher than the historical trend, and we are in transition period with the switching from Lilly to Amphastar. | The demands have been higher than the historical trend, and we are in transition period with the switching from Lilly to Amphastar. |
| Health Canada comments |